Eleusis: Transforming Psychedelics into Medicines


Eleusis is developing psychedelic therapies intended to integrate into the modern, insurance supported healthcare system if FDA-approved. Our lead candidate, ELE-Psilo, is a second-generation #psilocybin-derived treatment designed to target #depression and to be administered via IV infusion, with the potential to offer a consistent, controlled and convenient experience for patients. Eleusis has announced a business combination agreement with Silver Spike Acquisition Corp II (Nasdaq: SPKB) anticipated to take the company public and to this accelerate its mission to bring novel and promising #psychedelic treatments to the patients that need them.

Eleusis Securities Marketing Statement: